INTRACELLULAR PHARMACOKINETICS OF 2-CHLORODEOXYADENOSINE IN LEUKEMIA-CELLS FROM PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA

被引:0
|
作者
ALESSISEVERINI, S
GATI, WP
BELCH, AR
PATERSON, ARP
机构
[1] UNIV ALBERTA, DEPT PHARMACOL, EDMONTON, AB T6G 2H7, CANADA
[2] CROSS CANC INST, DEPT MED, EDMONTON, AB T6G 1Z2, CANADA
关键词
2-CHLORODEOXYADENOSINE (2-CDA); NITROBENZYLTHIOINOSINE (NBMPR); CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); NUCLEOSIDE TRANSPORT INHIBITION; TRANSPORTER-MEDIATED EFFLUX; EFFLUX BLOCKADE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2-Chlorodeoxyadenosine (2-CdA) is an important agent in the treatment of hairy cell leukemia and chronic lymphocytic leukemia (CLL). Others have reported that levels of 2-CdA phosphates present in human leukemia cells decline rapidly when the cells are in 2-CdA-free medium (Santana et al. J Clin Oncol 1991; 9: 416-422). In the present study, time-courses of 2-CdA lass from CLL cells were biexponential: the mean half-life of the initial phase was 0.30 +/- 0.18 h; the presence of 0.5 mu M nitrobenzylthioinosine (NBMPR, a classical inhibitor of nucleoside transport) in the suspending medium, significantly decreased the initial rate of 2-CdA efflux (mean half-life, 0.43 +/- 0.22 h). As a consequence, AUCs (areas under time-course plots) were significantly higher in the NBMPR-treated cells (4.56 +/- 2.01 pmol . h/10(6) cells, n = 19) than in untreated control cells (3.83 +/- 1.74 pmol . h/10(6) cells; n = 19). 2-CdA was the principal efflux product released into the medium from 2-CdA-loaded CLL cells. We conclude that nucleoside transport processes contribute to the efflux of 2-CdA from CLL cells and that NBMPR may be useful as a retentive agent.
引用
收藏
页码:1674 / 1679
页数:6
相关论文
共 50 条
  • [41] CHRONIC LYMPHOCYTIC LEUKEMIA CELL SEGMENTATION FROM MICROSCOPIC BLOOD IMAGES USING WATERSHED ALGORITHM AND OPTIMAL THRESHOLDING
    Mohammed, Emad A.
    Mohamed, Mostafa M. A.
    Naugler, Christopher
    Far, Behrouz H.
    2013 26TH ANNUAL IEEE CANADIAN CONFERENCE ON ELECTRICAL AND COMPUTER ENGINEERING (CCECE), 2013, : 485 - 489
  • [42] Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States
    Kabadi, Shaum M.
    Goyal, Ravi K.
    Nagar, Saurabh P.
    Kaye, James A.
    Davis, Keith L.
    CANCER MEDICINE, 2019, 8 (08): : 3803 - 3810
  • [43] Increased IL-10/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia
    Pang, Nannan
    Zhang, Rui
    Li, Jinhua
    Zhang, Zhenghao
    Yuan, Hailong
    Chen, Gang
    Zhao, Fang
    Wang, Lei
    Cao, Haizhou
    Qu, Jianhua
    Ding, Jianbing
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 40 : 57 - 64
  • [44] V-KAPPA GENE SEGMENTS REARRANGED IN CHRONIC LYMPHOCYTIC-LEUKEMIA ARE DISTRIBUTED OVER A LARGE PORTION OF THE V-KAPPA LOCUS AND DO NOT SHOW SOMATIC MUTATION
    WAGNER, SD
    LUZZATTO, L
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (02) : 391 - 397
  • [45] T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations
    Vlachonikola, Elisavet
    Pechlivanis, Nikolaos
    Karakatsoulis, Georgios
    Sofou, Electra
    Gkoliou, Glykeria
    Jeromin, Sabine
    Stavroyianni, Niki
    Ranghetti, Pamela
    Scarfo, Lydia
    Osterholm, Cecilia
    Mansouri, Larry
    Notopoulou, Sofia
    Siorenta, Alexandra
    Anagnostopoulos, Achilles
    Ghia, Paolo
    Haferlach, Claudia
    Rosenquist, Richard
    Psomopoulos, Fotis
    Kouvatsi, Anastasia
    Baliakas, Panagiotis
    Stamatopoulos, Kostas
    Chatzidimitriou, Anastasia
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [46] Recurrent Chromosome Abnormalities Define Nonoverlapping Unique Subgroups of Tumors in Patients With Chronic Lymphocytic Leukemia and Known Karyotypic Abnormalities
    Jimenez-Zepeda, Victor H.
    Chng, Wee Joo
    Schop, Roelandt F. J.
    Braggio, Esteban
    Leis, Jose F.
    Kay, Neil
    Fonseca, Rafael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04) : 467 - 476
  • [47] Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia
    Kern, Wolfgang
    Bacher, Ulrike
    Haferlach, Claudia
    Alpermann, Tamara
    Dicker, Frank
    Schnittger, Susanne
    Haferlach, Torsten
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (03) : 145 - 150
  • [48] Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro
    Dilley, Robert L.
    Poh, Weijie
    Gladstone, Douglas E.
    Herman, James G.
    Showel, Margaret M.
    Karp, Judith E.
    McDevitt, Michael A.
    Pratz, Keith W.
    LEUKEMIA RESEARCH, 2014, 38 (03) : 411 - 417
  • [49] Impact of biological and genetic features of leukemic cells on the occurrence of "shark fins" in the WPC channel scattergrams of the Sysmex XN hematology analyzers in patients with chronic lymphocytic leukemia
    Egger, Margot
    Fang, I-Fei
    Quehenberger, Franz
    Robier, Christoph
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2025,
  • [50] Characterization of Three Somatic Mutations in the 3′UTR of RRAS2 and Their Inverse Correlation with Lymphocytosis in Chronic Lymphocytic Leukemia
    Lacuna, Marta
    Hortal, Alejandro M.
    Cifuentes, Claudia
    Gonzalo, Tania
    Alcoceba, Miguel
    Bastos, Miguel
    Bustelo, Xose R.
    Gonzalez, Marcos
    Alarcon, Balbino
    CELLS, 2023, 12 (23)